FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285499360> ?p ?o ?g. }

• W4285499360 endingPage "604.e5" @default.
• W4285499360 startingPage "592" @default.
• W4285499360 abstract "Tralokinumab, as monotherapy or in combination with topical corticosteroids (TCS), has exhibited marked efficacy through 52 weeks in phase 3 trials of adults with moderate-to-severe atopic dermatitis and additional efficacy in a long-term extension trial. Early changes in patient-reported symptoms have not been communicated.To evaluate early changes in patient-reported outcomes (PROs) across the ECZTRA 1, 2, and 3 tralokinumab trials.Monotherapy data (ECZTRA 1 + 2) was pooled; ECZTRA 3 evaluated tralokinumab plus optional TCS. The PROs were assessed through the trials.A total of 1596 and 380 patients were randomized in ECZTRA 1 and 2 and ECZTRA 3, respectively. Baseline demographics and clinical characteristics were similar between groups. Early separation from placebo was observed in percentage improvement in worst average daily pruritus numerical rating score (NRS) (week 1, ECZTRA 1 + 2; week 2, ECZTRA 3) and from day 2 in ECZTRA 1 and 2 daily data. More tralokinumab-treated patients achieved clinically meaningful improvements (≥ 4 points) in NRS by week 2 (ECZTRA 1 + 2) or week 3 (ECZTRA 3) vs placebo. Improvements in eczema-related sleep NRS were seen within 2 weeks (week 1, ECZTRA 1 + 2; week 2, ECZTRA 3), supported by similar improvements in other sleep measures. Meaningful changes in Dermatology Life Quality Index were observed from week 2 (ECZTRA 1 + 2). Results were supported by numerical differences from placebo in Patient-Oriented Eczema Measure total score (week 2, both data sets).Tralokinumab with or without TCS exhibited early and clinically meaningful improvements vs placebo in several PROs, which may be beneficial to patients because atopic dermatitis symptom relief is a key treatment concern for patients." @default.
• W4285499360 created "2022-07-15" @default.
• W4285499360 creator A5011739266 @default.
• W4285499360 creator A5015905197 @default.
• W4285499360 creator A5064365679 @default.
• W4285499360 creator A5073722593 @default.
• W4285499360 creator A5075104139 @default.
• W4285499360 creator A5082065479 @default.
• W4285499360 creator A5083749846 @default.
• W4285499360 creator A5089796227 @default.
• W4285499360 date "2022-11-01" @default.
• W4285499360 modified "2023-09-25" @default.
• W4285499360 title "Patient-oriented measures for phase 3 studies of tralokinumab for the treatment of atopic dermatitis (ECZTRA 1, 2, and 3)" @default.
• W4285499360 cites W1561650855 @default.
• W4285499360 cites W2019286335 @default.
• W4285499360 cites W2057098942 @default.
• W4285499360 cites W2058562555 @default.
• W4285499360 cites W2096991001 @default.
• W4285499360 cites W2109260550 @default.
• W4285499360 cites W2117359358 @default.
• W4285499360 cites W2117983771 @default.
• W4285499360 cites W2120110016 @default.
• W4285499360 cites W2129960616 @default.
• W4285499360 cites W2166281097 @default.
• W4285499360 cites W2258546719 @default.
• W4285499360 cites W2272092695 @default.
• W4285499360 cites W2514613686 @default.
• W4285499360 cites W2520198258 @default.
• W4285499360 cites W2557191479 @default.
• W4285499360 cites W2559769990 @default.
• W4285499360 cites W2623278488 @default.
• W4285499360 cites W2883568898 @default.
• W4285499360 cites W2885934404 @default.
• W4285499360 cites W2888917798 @default.
• W4285499360 cites W2899320385 @default.
• W4285499360 cites W2904694536 @default.
• W4285499360 cites W2908925106 @default.
• W4285499360 cites W2914603675 @default.
• W4285499360 cites W2950045858 @default.
• W4285499360 cites W2954110843 @default.
• W4285499360 cites W2970372587 @default.
• W4285499360 cites W2981957052 @default.
• W4285499360 cites W3004432356 @default.
• W4285499360 cites W3090227268 @default.
• W4285499360 cites W3091046625 @default.
• W4285499360 cites W3098648594 @default.
• W4285499360 cites W3105761540 @default.
• W4285499360 cites W3122966962 @default.
• W4285499360 cites W4211145137 @default.
• W4285499360 cites W4295259359 @default.
• W4285499360 doi "https://doi.org/10.1016/j.anai.2022.07.007" @default.
• W4285499360 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35843520" @default.
• W4285499360 hasPublicationYear "2022" @default.
• W4285499360 type Work @default.
• W4285499360 citedByCount "4" @default.
• W4285499360 countsByYear W42854993602023 @default.
• W4285499360 crossrefType "journal-article" @default.
• W4285499360 hasAuthorship W4285499360A5011739266 @default.
• W4285499360 hasAuthorship W4285499360A5015905197 @default.
• W4285499360 hasAuthorship W4285499360A5064365679 @default.
• W4285499360 hasAuthorship W4285499360A5073722593 @default.
• W4285499360 hasAuthorship W4285499360A5075104139 @default.
• W4285499360 hasAuthorship W4285499360A5082065479 @default.
• W4285499360 hasAuthorship W4285499360A5083749846 @default.
• W4285499360 hasAuthorship W4285499360A5089796227 @default.
• W4285499360 hasBestOaLocation W42854993601 @default.
• W4285499360 hasConcept C126322002 @default.
• W4285499360 hasConcept C142724271 @default.
• W4285499360 hasConcept C144024400 @default.
• W4285499360 hasConcept C149923435 @default.
• W4285499360 hasConcept C159110408 @default.
• W4285499360 hasConcept C16005928 @default.
• W4285499360 hasConcept C168563851 @default.
• W4285499360 hasConcept C1862650 @default.
• W4285499360 hasConcept C204787440 @default.
• W4285499360 hasConcept C27081682 @default.
• W4285499360 hasConcept C2776173921 @default.
• W4285499360 hasConcept C2778329239 @default.
• W4285499360 hasConcept C2779134260 @default.
• W4285499360 hasConcept C2779951463 @default.
• W4285499360 hasConcept C2780084366 @default.
• W4285499360 hasConcept C2780699399 @default.
• W4285499360 hasConcept C535046627 @default.
• W4285499360 hasConcept C71924100 @default.
• W4285499360 hasConceptScore W4285499360C126322002 @default.
• W4285499360 hasConceptScore W4285499360C142724271 @default.
• W4285499360 hasConceptScore W4285499360C144024400 @default.
• W4285499360 hasConceptScore W4285499360C149923435 @default.
• W4285499360 hasConceptScore W4285499360C159110408 @default.
• W4285499360 hasConceptScore W4285499360C16005928 @default.
• W4285499360 hasConceptScore W4285499360C168563851 @default.
• W4285499360 hasConceptScore W4285499360C1862650 @default.
• W4285499360 hasConceptScore W4285499360C204787440 @default.
• W4285499360 hasConceptScore W4285499360C27081682 @default.
• W4285499360 hasConceptScore W4285499360C2776173921 @default.
• W4285499360 hasConceptScore W4285499360C2778329239 @default.
• W4285499360 hasConceptScore W4285499360C2779134260 @default.
• W4285499360 hasConceptScore W4285499360C2779951463 @default.

• next